Brief report: Impact of consolidation durvalumab on unresectable non-small lung cancer with driver mutations.

Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-09 DOI:10.1016/j.ctarc.2025.100863

Jason C S Ho, K M Cheung

{"title":"Brief report: Impact of consolidation durvalumab on unresectable non-small lung cancer with driver mutations.","authors":"Jason C S Ho, K M Cheung","doi":"10.1016/j.ctarc.2025.100863","DOIUrl":null,"url":null,"abstract":"<p><p>Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the 118 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. The addition of durvalumab did not improve real-world recurrence-free survival (rwRFS) in patients with these mutations (hazard ratio [HR] 0.852, 95 % confidence interval [CI] 0.394 - 1.843, p= 0.683). In contrast, rwRFS significantly improved for patients without common mutations (HR 0.342, 95 % CI 0.203 - 0.577, p< 0.001). These findings suggest that consolidation durvalumab may not be beneficial for patients with common driver mutations, underscoring the need for personalized treatment strategies in this population.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"100863"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ctarc.2025.100863","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the 118 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. The addition of durvalumab did not improve real-world recurrence-free survival (rwRFS) in patients with these mutations (hazard ratio [HR] 0.852, 95 % confidence interval [CI] 0.394 - 1.843, p= 0.683). In contrast, rwRFS significantly improved for patients without common mutations (HR 0.342, 95 % CI 0.203 - 0.577, p< 0.001). These findings suggest that consolidation durvalumab may not be beneficial for patients with common driver mutations, underscoring the need for personalized treatment strategies in this population.

查看原文本刊更多论文

简要报告：巩固durvalumab对不可切除的非小肺癌驱动突变的影响。

不可切除的III期非小细胞肺癌（NSCLC）预后不良。太平洋试验确定了化疗后巩固杜伐单抗作为标准治疗；然而，其对驱动突变患者的疗效仍不确定。这项回顾性队列研究分析了香港三家肿瘤中心的数据，涵盖时间为2019年1月至2022年12月。在接受最终放化疗的118例患者中，33例有常见的驱动突变，包括EGFR突变、ALK重排、ROS1重排和RET融合。durvalumab的加入并没有改善这些突变患者的真实世界无复发生存率（rwRFS）（风险比[HR] 0.852, 95%可信区间[CI] 0.394 - 1.843, p= 0.683）。相比之下，无常见突变患者的rwRFS显著改善（HR 0.342, 95% CI 0.203 - 0.577, p< 0.001）。这些发现表明，巩固durvalumab可能对具有常见驱动突变的患者没有益处，强调了在这一人群中需要个性化的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.